November 1, 2010
Strides Arcolab Limited, a pharmaceutical company headquartered in Bangalore, India, on Friday announced it "has received tentative approval from the United States Food and Drug Administration for one [abbreviated] new drug application (ANDA) for fixed dose combination of Lamivudine and Zidovudine tablets 150 mg/300 mg under the expedited review provisions" of PEPFAR, PHARMABIZ.com reports. Strides Arcolab "has so far received 16 PEPFAR approvals," according to the news service (10/29). "The company supplies ARV [antiretroviral] products to global procurement agencies and this approval adds to the overall basket of medicines available," according to a Strides Arcolab press release (.pdf) (10/29).
Back to other news for November 2010
This information was reprinted from kff.org with permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives, and sign up for email delivery. © Henry J. Kaiser Family Foundation. All rights reserved.